
- Best-supported hair treatment
- Minoxidil (FDA-approved, OTC); finasteride for some
- Time to see hair results
- Usually 6 to 12 months of consistent use
- Skin after menopause
- About 30% of collagen lost in the first 5 years (AAD)
- GHK-Cu
- FDA Category 1 for compounding, non-injectable routes only
What changes, and why
Skin and hair both respond to hormones, genetics and time. The American Academy of Dermatology notes that women's skin loses about 30% of its collagen in the first five years after menopause, then about 2% a year for the next two decades. Skin also holds less water and becomes thinner, which makes it drier and quicker to bruise.
Hair changes follow a similar arc. Female pattern hair loss is the most common type of hair loss in women, usually begins in midlife and is mainly hereditary, though it becomes more common after menopause. In men, pattern hair loss is driven by DHT, a testosterone byproduct, acting on genetically sensitive follicles.
Peptides in skin care
Cosmetic peptides are short amino acid chains added to creams and serums with the aim of signaling skin cells to make collagen or calming irritation. The AAD says products containing retinol or peptides may support collagen, alongside sunscreen and a good moisturizer.
Cosmetic studies are often small, short and funded by manufacturers, and they don't show the kind of results a prescription treatment would need to prove. Peptide creams are a reasonable part of a routine, but sunscreen and retinoids have stronger evidence for photoaging.
Copper peptide (GHK-Cu)
GHK-Cu is a naturally occurring copper-binding peptide used in skin and hair products. It's promoted for collagen support and wound healing, mostly based on laboratory and small cosmetic studies.
In the FDA's 2026 list of substances nominated for compounding, GHK-Cu appears in Category 1, meaning it is under evaluation, for non-injectable routes only; the nomination for injectable use was withdrawn. The FDA plans to consult its compounding advisory committee about it before the end of February 2027. Injectable GHK-Cu marketed for anti-aging falls outside that category and is not FDA-approved.
What actually works for thinning hair
- Minoxidil: FDA-approved over the counter for women in 2% and 5% strengths and the treatment dermatologists recommend most. Some extra shedding is common in the first two to eight weeks.
- Finasteride: lowers DHT. MedlinePlus lists it for male pattern hair loss in men; dermatologists sometimes use it off-label in women who can't become pregnant. It can cause sexual side effects and mood changes, and women who are or could become pregnant shouldn't handle crushed or broken tablets.
- Spironolactone and other prescription pills are used off-label for female pattern hair loss.
- Results usually need 6 to 12 months of consistent use, and hair loss resumes after stopping.
- Low-level laser devices and platelet-rich plasma show promise but need more research.
Rule out other causes first
Not all thinning is pattern hair loss. Low iron stores, thyroid disease, recent illness or surgery, rapid weight loss (including on a GLP-1 medicine), some medicines and high stress can all trigger shedding. A dermatologist should confirm the diagnosis when it's unclear, and simple labs can identify treatable contributors.
The hormone link
For women in perimenopause and menopause, falling estrogen affects skin thickness, moisture and hair. Hormone therapy is prescribed to treat menopause symptoms such as hot flashes, not as a cosmetic treatment, though some women notice skin changes as a side benefit.
Your clinician can help weigh these effects as part of your broader plan.
Daily habits with the best return
- Broad-spectrum sunscreen, SPF 30 or higher, on exposed skin every day, including winter
- A gentle cleanser instead of soap, and moisturizer after bathing
- A retinoid at night if your skin tolerates it
- Enough protein and iron to support hair growth
- Gentle hair care: limit tight styles, high heat and harsh chemical treatments
Managing expectations
Realistic goals for hair are to slow loss and regain some density over a year, not to restore your 30-year-old hairline. For skin, the biggest levers are daily broad-spectrum SPF 30 or higher, not smoking, good sleep, adequate protein and a retinoid where tolerated.
At HealifyMD, the 4-in-1 Hair Loss Treatment is a compounded formula, typically pairing minoxidil with a 5-alpha-reductase inhibitor such as finasteride, priced at $199 one-time and confirmed at your eligibility review. Compounded medications are not FDA-approved. HealifyMD doesn't prescribe peptides for cosmetic skin or hair use.
Common questions
What's actually prescribed for hair thinning?
Minoxidil and, for some people, finasteride or spironolactone are the most established options. Peptides aren't a first-line hair loss treatment.
Do peptide skin creams work?
They may modestly support collagen as part of a routine, but sunscreen and retinoids have stronger evidence for aging skin.
Is GHK-Cu safe to inject?
Injectable GHK-Cu isn't FDA-approved, and its injectable compounding nomination was withdrawn. Long-term safety of injections isn't established.
Could hormones be affecting my skin and hair?
Yes. Menopause reduces collagen and skin moisture, and hormone shifts can contribute to hair thinning in both women and men.
How long before I'd see results for hair?
Most treatments need 6 to 12 months of consistent use, and early shedding with minoxidil is common.
Can a GLP-1 medicine cause hair loss?
Rapid weight loss from any cause can trigger temporary shedding. It usually settles, but tell your clinician if it happens.
Is finasteride safe for women?
It's sometimes used off-label in women who can't become pregnant, because exposure during pregnancy may harm the fetus. Your clinician will review your situation.
Sources
We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.
- Skin Care During MenopauseAmerican Academy of Dermatology
- Female Pattern Hair LossAmerican Academy of Dermatology
- FinasterideMedlinePlus (U.S. National Library of Medicine)
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories list)U.S. Food and Drug Administration
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration
- Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration